Comparison Between Classical 4-point Canne and 4-roll Canne on Gait Parameters (Gait Speed and Energy Cost) as Walking Aids After Stroke. A Multicentric Randomized Controled Cross-over Study
Stroke patients frequently necessitate walking aids such as 4-point canne. However, the 4-point canne has to be lifted by the patient which limited gait speed. The adjunction of small wheel below the 4 point of the canne (4-roll) gives the possibility to the patient to walk without having to lift the canne as it will roll over the ground. The aim of our study is to compare gait parameters (gait speed and energy cost) with a classical 4-point canne and with 4-roll canne.
NCT02279069 — Stroke
Status: Completed
http://inclinicaltrials.com/stroke/NCT02279069/
Prevalence and Risk Factors of Arterial Insufficiency in Patients With HIV / AIDS
The purpose of this study is to determine the risk factors associated with the occurrence of arterial insufficiency in patients with HIV / AIDS, and to identify the prevalence of this disease. The estimated prevalence is 10%, similar to that reported in the general population.
NCT02264509 — HIV
Status: Completed
http://inclinicaltrials.com/hiv/NCT02264509/
A Randomized Controlled Trial of Cognitive Behavior Therapy for Insomnia With Persons Living With HIV/AIDS
The proposed study will consist of a randomized controlled trial (RCT) comparing a known efficacious treatment for insomnia (CBT-I) to a sleep hygiene (SH) comparison condition.
NCT02259101 — HIV
Status: Completed
http://inclinicaltrials.com/hiv/NCT02259101/
Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer
The goal of this clinical study is to find out if certain instruments/devices, such as wide field fluorescence imaging point spectroscopy and/or brush cytology, can help health care providers find mouth cancer more quickly than a standard oral clinical exam.
NCT02251639 — Head and Neck Cancer
Status: Withdrawn
http://inclinicaltrials.com/head-and-neck-cancer/NCT02251639/
Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS
The aim of the Post Marketing Study (PMS) is to evaluate the efficacy and safety profile of nevirapine in the management of the HIV/AIDS in an open environment.
NCT02191215 — Acquired Immunodeficiency Syndrome
Status: Completed
http://inclinicaltrials.com/acquired-immunodeficiency-syndrome/NCT02191215/
Botswana Vitamin D Supplementation Study in HIV/AIDS
The goal is to determine the vit D supplementation dose that safely results in optimal serum vitamin D (25D) concentrations in HIV-infected children and adults living in Botswana. To do this the investigators will test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement over a 12-week period in 60 children and adults with HIV/AIDS living in Botswana (5.0 to 50.9 yrs), to assess safety as determined by serum calcium and 25D concentrations and efficacy to replete vit D status as determined by achieving a minimum serum 25D concentration of 32 ng/mL (80 nmol/L).
NCT02189902 — HIV
Status: Completed
http://inclinicaltrials.com/hiv/NCT02189902/
PREVALENCE of HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND) in a SCHOOL of MEDICINE HIV/AIDS OUTPATIENT CLINIC
1. To determine, in the Quillen College of Medicine HIV+ outpatient clinic, the prevalence of - NC (normal cognition ) - ANI (asymptomatic neurocognitive impairment ) - MCD (mild cognitive disorder ) - HAD (HIV-associated dementia ) 2. To determine whether the following variables affect the three categories of HAND - Time since first diagnosis of HIV infection - Anti-viral medications used - Age - Gender
NCT02187796 — HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)
Status: Completed
http://inclinicaltrials.com/hiv-associated-neurocognitive-disorder-hand/NCT02187796/
Effect of Treatment Nutritional With Supplementation About Biochemical Profile and Anthropometry in Adult Patients With HIV/AIDS
To evaluate if nutritional treatment with nutritional supplementation of dietary fiber reduces cholesterol levels and triglycerides (dyslipidemia) in patients with HIV/AIDS receiving antiretroviral therapy (HAART).
NCT02180035 — HIV
Status: Completed
http://inclinicaltrials.com/hiv/NCT02180035/
The Thai Red Cross AIDS Research Centre
OBJECTIVES 1. To determine the prevalence and incidence of anal HPV infection, including infection with high-risk HPV types, among MSM in Indonesia, Malaysia, and Thailand. 2. To study the prevalence and incidence of HGAIN among these MSM. 3. To evaluate risk factors, including HIV status, for anal high-risk HPV infection and HGAIN among these MSM. Study population An approximately 75 HIV-positive and 75 HIV-negative MSM who attended the study clinic in Kuala Lumpur, Jakarta, and Bangkok will be enrolled. The study will also enroll 185 HIV-positive and 95 HIV-negative MSM who are previous participants of the MSM VCT study. There will be approximately 260 HIV-positive and 170 HIV-negative MSM in total in this study.
NCT02155231 — HPV Testing
Status: Recruiting
http://inclinicaltrials.com/hpv-testing/NCT02155231/
Monotherapy in Africa: Evaluation of New Therapy
The aim of this pilot study is to assess the feasibility, efficacy and safety of Darunavir/ritonavir 800/100 mg once daily (DRV/r) monotherapy as a switch-maintenance strategy for patients receiving second-line ART at Yaoundé Central Hospital in Cameroon. HIV-infected adults receiving second-line antiretroviral therapy (ART) for ≥3 months with 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) will undergo plasma HIV-1 RNA ("viral") load testing. Those with a viral load below 50 copies/ml (<50 cps/ml) will undergo a repeat test ideally 4-6 weeks later (allowed up to 12 weeks); if the viral load is confirmed as <50 cps/ml the patient will be invited to join the randomised phase of the study. Patients (n=150) will be randomised 1:2 to either continue the current triple ART regimen (n=50) or switch to DRV/r monotherapy (n=100). The primary end-point will be viral load suppression <400 cps/ml at week 24; secondary end-points will be viral load suppression <50 cps/ml at week 12 and week 24, safety, tolerability, and emergence of protease inhibitor (PI) drug-resistance. Patients will continue observational follow-up depending on the treatment arm they are randomized to. After week 48, patients will return to local standard of care. Pharmacokinetics (PK) and pharmacogenomics sub-study to correlate plasma concentrations of DRV to outcomes, HIV-1 drug resistance testing sub study to detect mutants archived at the time of first-line ART failure and measuring HIV DNA load will be performed, as well as a cost-effectiveness analysis will test the hypothesis that savings can be achieved by switching to DRV/r monotherapy without affecting quality of care. The primary virological objective is to evaluate efficacy in terms of the percentage of subjects who have plasma HIV-1 RNA levels <400 cps/ml after 24 weeks of follow-up following a switch to DRV/r monotherapy versus continuing triple therapy containing 2 NRTIs + LPV/r (or ATV/r) (FDA Snapshot method). Study hypothesis: we propose that maintenance therapy with DRV/r monotherapy is a feasible, effective and safe treatment option for patients receiving second-line ART in Yaoundé.
NCT02155101 — HIV/AIDS
Status: Completed
http://inclinicaltrials.com/hiv-aids/NCT02155101/